FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085200879> ?p ?o ?g. }

• W3085200879 endingPage "86" @default.
• W3085200879 startingPage "68" @default.
• W3085200879 abstract "Purpose As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS). Methods and Materials Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases. Results Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm3, 10 cm3, or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection. Conclusions The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks. As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS). Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases. Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm3, 10 cm3, or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection. The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks." @default.
• W3085200879 created "2020-09-21" @default.
• W3085200879 creator A5003019825 @default.
• W3085200879 creator A5004050829 @default.
• W3085200879 creator A5007170568 @default.
• W3085200879 creator A5015138770 @default.
• W3085200879 creator A5018109835 @default.
• W3085200879 creator A5028403057 @default.
• W3085200879 creator A5033231728 @default.
• W3085200879 creator A5059651661 @default.
• W3085200879 creator A5067679342 @default.
• W3085200879 creator A5072792947 @default.
• W3085200879 creator A5081365127 @default.
• W3085200879 creator A5083273831 @default.
• W3085200879 creator A5085651347 @default.
• W3085200879 date "2021-05-01" @default.
• W3085200879 modified "2023-10-17" @default.
• W3085200879 title "Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain" @default.
• W3085200879 cites W1493598570 @default.
• W3085200879 cites W1497025961 @default.
• W3085200879 cites W152319095 @default.
• W3085200879 cites W1605447452 @default.
• W3085200879 cites W1640859808 @default.
• W3085200879 cites W1653443644 @default.
• W3085200879 cites W1847229489 @default.
• W3085200879 cites W1872520013 @default.
• W3085200879 cites W1965749846 @default.
• W3085200879 cites W1967067732 @default.
• W3085200879 cites W1968626722 @default.
• W3085200879 cites W1972327512 @default.
• W3085200879 cites W1974029992 @default.
• W3085200879 cites W1978002281 @default.
• W3085200879 cites W1980825581 @default.
• W3085200879 cites W1981863549 @default.
• W3085200879 cites W1984221014 @default.
• W3085200879 cites W1991407037 @default.
• W3085200879 cites W1995998803 @default.
• W3085200879 cites W1996588200 @default.
• W3085200879 cites W2004575539 @default.
• W3085200879 cites W2005743296 @default.
• W3085200879 cites W2009217240 @default.
• W3085200879 cites W2013636903 @default.
• W3085200879 cites W2015902877 @default.
• W3085200879 cites W2020050859 @default.
• W3085200879 cites W2024257232 @default.
• W3085200879 cites W2041169558 @default.
• W3085200879 cites W2041876348 @default.
• W3085200879 cites W2043945205 @default.
• W3085200879 cites W2044383209 @default.
• W3085200879 cites W2045492424 @default.
• W3085200879 cites W2051013939 @default.
• W3085200879 cites W2054474589 @default.
• W3085200879 cites W2057451516 @default.
• W3085200879 cites W2058718908 @default.
• W3085200879 cites W2060026632 @default.
• W3085200879 cites W2069289885 @default.
• W3085200879 cites W2069308124 @default.
• W3085200879 cites W2071032101 @default.
• W3085200879 cites W2071098381 @default.
• W3085200879 cites W2073662365 @default.
• W3085200879 cites W2080573864 @default.
• W3085200879 cites W2081867206 @default.
• W3085200879 cites W2082282806 @default.
• W3085200879 cites W2083128109 @default.
• W3085200879 cites W2100595880 @default.
• W3085200879 cites W2107328538 @default.
• W3085200879 cites W2111137187 @default.
• W3085200879 cites W2114058673 @default.
• W3085200879 cites W2122586261 @default.
• W3085200879 cites W2127682576 @default.
• W3085200879 cites W2132730716 @default.
• W3085200879 cites W2136706275 @default.
• W3085200879 cites W2136963436 @default.
• W3085200879 cites W2142873417 @default.
• W3085200879 cites W2145376545 @default.
• W3085200879 cites W2146269545 @default.
• W3085200879 cites W2148531306 @default.
• W3085200879 cites W2148845568 @default.
• W3085200879 cites W2149791601 @default.
• W3085200879 cites W2153140684 @default.
• W3085200879 cites W2156098321 @default.
• W3085200879 cites W2157405811 @default.
• W3085200879 cites W2158777895 @default.
• W3085200879 cites W2159314579 @default.
• W3085200879 cites W2165980996 @default.
• W3085200879 cites W2167348354 @default.
• W3085200879 cites W2169943019 @default.
• W3085200879 cites W2189168527 @default.
• W3085200879 cites W2191768182 @default.
• W3085200879 cites W2225066468 @default.
• W3085200879 cites W2253775193 @default.
• W3085200879 cites W2259606385 @default.
• W3085200879 cites W2272163797 @default.
• W3085200879 cites W2273903353 @default.
• W3085200879 cites W2292825275 @default.
• W3085200879 cites W2302127234 @default.
• W3085200879 cites W2312464030 @default.
• W3085200879 cites W2342601826 @default.

• next